Fusion Pharmaceuticals
Fusion Pharmaceuticals develops next-generation radiopharmaceuticals using its Targeted Alpha Therapies (TAT) platform and proprietary Fast-Clear™ linker technology to treat cancer. The company operates from Hamilton, Ontario, Canada, and Boston, Massachusetts, USA, and focuses on creating precision medicines that improve safety and efficacy in cancer treatment.
Company Overview
Fusion Pharmaceuticals specializes in the development of next-generation radiopharmaceuticals aimed at cancer treatment. The company employs its proprietary Targeted Alpha Therapies (TAT) platform along with Fast-Clear™ linker technology to enhance the safety and effectiveness of its precision medicines. Fusion Pharmaceuticals spun out from the Centre for Probe Development and Commercialization (CPDC) and maintains locations in Hamilton, Ontario, Canada, and Boston, Massachusetts, USA.
Proprietary Technologies
Fusion Pharmaceuticals utilizes a combination of its TAT platform and Fast-Clear™ linker technology to deliver precision radiopharmaceuticals. The Fast-Clear™ linker technology is designed to improve the safety of radiopharmaceuticals by facilitating the rapid excretion of medical isotopes that do not bind to cancer cells, thus reducing toxicity to healthy tissues. This technology is also meant to offer a wider therapeutic window, potentially resulting in a safer and more effective treatment.
Leading Programs
Fusion Pharmaceuticals is actively developing several lead programs. FPI-2265 targets prostate-specific membrane antigen (PSMA) expressed in prostate cancer using the small molecule 225Ac-PSMA I&T. FPI-1434 is designed to target IGF-1R on cancer cells and combines an antibody for IGF-1R with Fusion's Fast-Clear™ linker technology to deliver alpha particles to cancer cells. FPI-2059 is another advanced program that targets neurotensin receptor 1 (NTSR1) for the treatment of various solid tumors. Additionally, a Phase 1 clinical trial is underway for FPI-1434 in patients with solid tumors expressing IGF-1R.
Clinical Trials and Research
Fusion Pharmaceuticals conducts a Phase 1 clinical trial investigating FPI-1434 in patients with solid tumors expressing IGF-1R. This trial aims to evaluate the efficacy and safety of the radiopharmaceutical when used alone or in combination with other treatments, such as checkpoint inhibitors and DNA damage repair inhibitors. The company aims to provide potential synergistic effects when used in combination with approved oncology therapies.
Funding and Financials
Fusion Pharmaceuticals successfully raised $105 million in an oversubscribed Series B financing round. This financial support is intended to scale up and ensure reliable commercial production of its targeted alpha therapeutics. The funding aims to facilitate the development and global commercialization of Fusion's innovative treatments, which are designed to offer enhanced tumor-killing capabilities and broad applicability across multiple tumor types.